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Summary
Objective: To assess the impact of admission to
different hospital types on early and 1-year out-
comes in patients with acute coronary syndrome
(ACS).
Methods: Between 1997 and 2009, 31010 ACS
patients from 76 Swiss hospitals were enrolled in
the AMIS Plus registry. Large tertiary institutions
with continuous (24 hour/7 day) cardiac catheter-
isation facilities were classified as type A hospitals,
and all others as type B. For 1-year outcomes, a
subgroup of patients admitted after 2005 were
studied.
Results: Eleven type A hospitals admitted
15987 (52%) patients and 65 type B hospitals
15023 (48%) patients. Patients admitted into B
hospitals were older, more frequently female, dia-
betic, hypertensive, had more severe comorbidi-
ties and more frequent non-ST segment elevation
(NSTE)-ACS/unstable angina (UA). STE-ACS
patients admitted into B hospitals received more
thrombolysis, but less percutaneous coronary in-
tervention (PCI). Crude in-hospital mortality and
major adverse cardiac events (MACE) were higher
in patients from B hospitals. Crude 1-year mortal-
ity of 3747ACS patients followed up was higher in
patients admitted into B hospitals, but no differ-
ences were found for MACE.After adjustment for
age, risk factors, type of ACS and comorbidities,
hospital type was not an independent predictor of
in-hospital mortality, in-hospital MACE, 1-year
MACE or mortality. Admission indicated a crude
outcome in favour of hospitalisation during duty-
hours while 1-year outcome could not document
a significant effect.
Conclusion: ACS patients admitted to smaller
regional Swiss hospitals were older, had more se-
vere comorbidities, more NSTE-ACS and re-
ceived less intensive treatment compared with the
patients initially admitted to large tertiary institu-
tions. However, hospital type was not an inde-
pendent predictor of early and mid-term out-
comes in these patients. Furthermore, our data
suggest that Swiss hospitals have been functioning
as an efficient network for the past 12 years.
Key words: acute coronary syndrome; outcome; in-
hospital mortality; 1-year mortality; hospital type
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Introduction
Outcome comparison at the hospital level is a
sensitive issue and has been intensively debated
with regard to the size of hospital and admission
during duty-hours compared to admission during
off-hours. Furthermore, the availability of catheter-
isation facilities could have an effect on the per-
formed therapies and outcome in patients with
acute myocardial infarction (AMI) [1]. Using only
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administrative data or denoting mortality rate as a
valuable indicator for the quality of healthcare de-
livery in one hospital could lead to false interpreta-
tions and confusion [2, 3]. However, hospital per-
formance measures are not tightly linked to patient
outcomes [4]. In cardiology, many clinical trials,
registries and databases have provided a wealth of
information to define new therapies and to improve
the quality of clinical care through evaluation of
both the care processes and outcomes of patients
with a wide range of conditions; the latter being
more important for studies of real-life situations.
Cardiovascular disease is presently the
number one cause of mortality in Switzerland and
in theWestern world. Even though the mortality
rate for ST-segment elevation acute coronary
syndrome (STE-ACS) has greatly decreased in
Switzerland [5], there is still considerable room
for improvement.
AMIS Plus is a large, prospective national reg-
istry collecting data on the whole spectrum of pa-
tients with ACS in Switzerland. It is now acknowl-
edged that only registries can provide information
on clinical characteristics, the treatment patients
actually receive and clinical evaluation. By investi-
gating mortality data it is possible to document
the implementation of new strategies and treat-
ments, and their value compared to randomised
trials. Longitudinal AMIS Plus data enables physi-
cians to identify deficits in medical care, imple-
ment the necessary changes in diagnostics and
therapeutic procedures and to document its im-
pact on clinical outcome in ACS patients.
The aim of this study was to assess if the type
of admission hospital had an impact on early and
1-year outcomes in patients with ACS in Switzer-
land.
Methods
The AMIS Plus project is a nationwide prospective
registry of patients with ACS admitted to hospitals in
Switzerland. The registry was initiated in 1997, and pa-
tient recruitment has since been ongoing. Participating
centres, ranging from community institutions to large ter-
tiary facilities, provide data for each patient through a
standardised electronic or paper-based questionnaire.
The data are centralised at the Institute of Social and Pre-
ventive Medicine of the University of Zurich, checked for
plausibility and consistency, and incomplete question-
naires are returned to the enrolment centres for comple-
tion. The registry was approved by the Over-Regional
Ethics Committee for Clinical Studies, the Swiss Board
for Data Security and all cantonal Ethic Commissions.
TheAMIS Plus project is officially supportedby the Swiss
Societies of Cardiology, Internal Medicine and Intensive
Care Medicine, and is sponsored by unrestricted grants
from the Swiss Heart Foundation as well as a number of
pharmaceutical and medical device companies (listed in
the acknowledgements). Details of the AMIS Plus Project
have been published elsewhere [6–10].
The AMIS Plus Steering Committee decided that
follow-up data be included in theAMIS Plus project start-
ing in 2005, under the condition that follow-up investiga-
tion requires written approval.
Participating centres
Between January 1997 and June 2009, 76 hospitals
participated in the AMIS Plus project. Large tertiary
teaching institutions with continuous (24 hour/7 day) car-
diac catheterisation facilities were classified as type A hos-
pitals. All other participating hospitals were classified as
type B. During this period, the number of catheter labo-
ratories and procedural volume increased; in part due to
private hospitals purchasing such a unit and therefore is
no longer necessarily identical with the hospital type.
This was taken into account and additional analyses were
carried out.
Duty-hours were from 7 a.m. to 7 p.m. on weekdays
and off-hours were from 7 p.m. to 7 a.m. on weekdays or
entire weekends.
Patients
The AMIS Plus registry included all patients with
ACS: AMI, defined by characteristic symptoms and/or
electrocardiogram (ECG) changes and raised biomarker
levels (troponin according to hospital-specific assay cut-
offs or total creatine kinase or creatine kinaseMB fraction
at least twice the upper limit of normal), ACS with mini-
mal necrosis (symptoms or ECG changes compatible with
ACS and cardiac biomarker levels below the cut-off for
MI) and unstable angina (UA; symptoms or ECG changes
compatible with ACS without raised levels of cardiac
biomarkers). Patients were also categorised as having
STE-ACS or non-STE-ACS (NSTE-ACS) based on ini-
tial ECG findings. Classification of STE-ACS included
evidence of ACS as described above and ST-segment ele-
vation and/or presumed new left bundle branch block
(LBBB) on the initial ECG. NSTE-ACS included pa-
tients with ischaemic symptoms, ST-segment depression
or T-wave abnormalities in the absence of ST-elevation
on the initial ECG.
All ACS patients enrolled in the AMIS Plus registry
from January 1997 to June 2009 were included for analy-
sis of early outcome according to hospital type. Since
2005, a subset of 53 hospitals has collected follow-up in-
formation at 3 and 12 months after hospital discharge.
Mid-term outcome analysis was performed using data
from the patients who were asked and consented to par-
ticipate. These patients were interviewed 3 months and
1 year after the initial hospitalisation using the standard-
ised patients’ questionnaire.
Early outcome was defined as in-hospital mortality
or as a composite endpoint of major adverse cardiac
events (MACE) which included reinfarction, a cerebro-
vascular event or death during hospitalisation. Outcome
at 1-year follow-up was defined as mortality within 1 year
after discharge or as a composite endpoint of 1-year
MACE, which included reinfarction, any re-hospitalisa-
tion due to cardiovascular disease and/or death.
Statistical analyses
Data are presented as the proportion of valid cases
for discrete variables and as means ± standard deviations
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and/or medians with interquartile ranges for continuous
variables. Differences in baseline characteristics were
compared using either the unpaired t test or the Mann-
Whitney U test and the Pearson chi square test. Statistics
for each table are based on all cases with valid data within
the specified ranges for all variables in each table. Multi-
variate regression of complete cases was used to analyse
the independent effect of hospital type on outcome, ad-
justing for the following variables: age, gender, Killip clas-
sification at admission, time between symptom onset and
admission, history of diabetes, hypertension, dyslipi-
daemia, current smokers, obesity (BMI >30 kg/m
2
),
ST-segment elevation and/or new LBBB at initial ECG,
the weighted Charlson score for comorbidities [11] and
transfer. These variables were selected in former publica-
tions because they were shown to be independent predic-
tors of in-hospital mortality.Results are presented as odds
ratio (OR) with a 95% confidence interval (95% CI). A
p value of <0.05 was considered significant. The SPSS
software (SPSS Inc., Chicago, Illinois; Version 17.0) was
used for all statistical analyses.
Results
Between January 1997 and June 2009, 31010
ACS patients from 76 Swiss hospitals were en-
rolled in the AMIS Plus registry. Eleven hospitals
were classified as type A hospitals with 15987
(52%) patients and 65 hospitals were classified as
type B hospitals with 15023 (48%) patients.
From a total of 5005 patients enrolled be-
tween June 2005 and June 2009 in the AMIS Plus
registry who were asked and consented to the fol-
low-up, 4671 were interviewed 3 months after dis-
charge and 3747 were interviewed again 1 year af-
ter discharge. Of these patients, 41% were from
type A hospitals and 59% from type B hospitals.
Baseline characteristics of the patients accord-
ing to hospital type are shown in table 1. Patients
admitted primarily to type B hospitals were signif-
icantly older, were more frequently female, dia-
betic and hypertensive, and more frequently pre-
sented with NSTE-ACS or UA.Of these patients,
27.0% had moderate or severe comorbidities
(Charlson Index greater than 2) compared with
21.6% of the patients admitted to the large hospi-
tals (p <0.001). In both typeA and type B hospitals,
around 7% of patients were in Killip classes
greater than II at admission, the time between
symptom onset and admission was similar, and a
comparable amount of the patients were admitted
during off-hours.
Performed therapies are depicted in table 2. In
comparison with patients from type A hospitals,
patients from type B hospitals were less likely to
receive aspirin (93.6% vs 95.0%; p <0.001), clopi-
dogrel (42.5% vs 67.9%; p <0.001) and GPIIb/IIIa
antagonists (17.3% vs 44.6%; p <0.001). Type B
Characteristics Total population
(n = 31010)
A hospitals
(n = 15987)
B hospitals
(n = 15023)
p-value (A vs. B)
Men (%) 72.4 75.0 69.7 <0.001
Age, mean years (SD) 65.6 (13.2) 64.0 (13.0) 67.3 (13.2) <0.001
Delay, median in minutes (inter-
quartile range)
240 (120, 705) 240 (120, 630) 240 (110, 785) 0.837
Admission during off-hours 14112/30453 (46.3) 7215/15579 (46.3) 6897/14874 (46.4) 0.927
History of coronary artery disease 8678/22178 (39.1) 4310/11625 (37.1) 4368/10553 (41.4) <0.001
Diabetes 5969/29807 (20.0) 12492/15399 (18.9) 3061/14408 (21.3) <0.001
Hypertension 17123/29557 (57.9) 8777/15389 (57.0) 8346/14168 (58.9) 0.001
Dyslipidaemia 15738/27587 (57.0) 8560/14858 (57.6) 7178/12729 (56.4) 0.042
Current smoking 10995/28858 (38.1) 6058/14723 (41.1) 4937/14135 (34.9) <0.001
Obesity (BMI >30 kg/m
2
) 4781/24653 (19.4) 2537/13329 (19.0) 2244/11324 (19.8) 0.125
STE-ACS 17980/30926 (58.1) 9660/15936 (60.6) 8320/14990 (55.5) <0.001
Killip classes >II 2168/30617 (7.1) 1097/15772 (7.0) 1071/14845 (7.2) 0.385
Comorbidities (Charlson weighted
Index)* N
21553 12078 9475 <0.001
0 (no comorbidities) (%) 53.1 55.5 49.9
1 (%) 23.0 22.9 23.2
2 (%) 11.1 10.7 11.7
=>3 (%) 12.8 10.9 15.3
* Comorbidities included: past history of myocardial infarction, cardiac insufficiency (NYHA III+IV), peripheral vascular disease (ST
III+IV), cerebrovascular disease, haemiplegia, dementia, chronic lung disease, connective tissue disease, peptic ulcer disease, diabetes
without and with target organ damage, liver disease, renal disease, malignant neoplasm, leukaemia, lymphoma, metastatic solid tumour
and AIDS.
Data are presented as n/N (%) unless stated otherwise.
Table 1
Patients’ baseline
characteristics
according to the
hospital type.
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hospital patients more frequently received low
molecular weight heparin whereas patients from
type A hospitals (41.9% vs 26.3%; p <0.001) more
frequently received unfractionated heparin (73.1%
vs 68.2%; p <0.001).
STE-ACS patients initially admitted to type B
hospitals received thrombolysis more frequently
than patients admitted to type A hospitals (23.1%
vs 13.9%; p <0.001). These patients also less fre-
quently underwent percutaneous coronary inter-
vention (PCI); primary PCI (31.1% vs 57.0%;
p <0.001) and any PCI (57.6% vs 79.1%; p <0.001).
Trends in PCI use in STE-ACS patients from
1997 to 2009 were the same for both groups of pa-
tients irrespective of hospital type.
Of the ACS patients, 15883 were admitted to
hospitals with continuous (7 day/24 hour) catheter
laboratory facilities, 2406 to hospitals with cathe-
ter laboratories available during duty hours and
12721 to hospitals without catheter laboratories.
All analyses were repeated using these facilities as
a determinant variable instead of the hospital type.
The results were similar resulting in no significant
differences.
In 2002, the localisation of PCI was added to
the AMIS Plus Questionnaire. From 16647 pa-
tients, 66.7% underwent intervention in the ad-
mission hospital and 5537 were transferred for in-
tervention. Patients transferred for intervention
were comparable with patients who underwent in-
tervention in the admission hospital with regard to
age (62.4 years vs 62.6 years; p = 0.46) and comor-
bidities (Charlson Score >= 3 17.3% vs 17.4%;
p = 0.81). Less patients died in-hospital if they
were transferred for PCI compared with patients
who underwent PCI in the admission hospital
(1.9% vs 3.5%; p <0.001). However, 1-year mor-
tality was similar regardless of whether patients
were transferred for interventions or not (2.0% vs
2.1%; p = 0.89). The patients initially admitted in
type B hospitals and not transferred to type A hos-
pitals for intervention were, in comparison with
transferred patients, on average 8 years older (69.6
± 13.1 y vs 61.9 ± 12.1 y), predominately women
(33.7% vs 24.8%), frequently had more severe co-
morbidities (Charlson Score ≥3; 22% vs 7%), ar-
rived on average 40 minutes later, were more often
in Killip classes >I and had STE-ACS less fre-
quently.
Complications and outcome according to hos-
pital type are presented in table 3. The complica-
tion rate during hospitalisation was higher in type
B hospitals (cardiogenic shock 7.9% vs 5.6%;
p <0.001, reinfarction 2.7% vs 1.6%; p <0.001) but
frequency of cerebrovascular events was the same
(1.0%). Crude in-hospital mortality was higher in
patients from type B hospitals than from type A
hospitals (7.4% vs 6.2%; p <0.001) as was MACE
(9.7% vs 7.9%; p <0.001).
Although the 1-year crude mortality was
higher in patients from type B hospitals (4.8% vs
2.8%; p = 0.003), the overall outcome of mortality,
reinfarction and any rehospitalisation due to car-
diovascular diseases was similar (24.5% vs 23.0%;
p = 0.086).
Hospital type, after adjustment for age, gen-
der, risk factors, delay, transfer, STE-ACS and co-
morbidities, was not an independent predictor of
in-hospital mortality (OR 0.94, 95% CI 0.76–
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Hospitals A Holspitals B
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Total population
(n = 31010)
A hospitals
(n = 15987)
B hospitals
(n = 15023)
p-value (A vs B)
Drugs
Aspirin 29144/30888 (94.4) 15127/15918 (95.0) 14017/14970 (93.6) <0.001
Clopidogrel 17086/30743 (55.6) 10771/15867 (67.9) 6315/14876 (42.5) <0.001
GPIIb/IIIa antagonist 8220/25441 (32.3) 6235/13967 (44.6) 1985/11474 (17.3) <0.001
Unfractionated heparin 21735/30745 (70.7) 11576/15839 (73.1) 10159/14906 (68.2) <0.001
Low molecular weight heparin 8472/25397 (33.4) 3660/13906 (26.3) 4812/11491 (41.9) <0.001
Beta blocker 21454/30734 (69.8) 11148/15822 (70.5) 10306/14912 (69.1) 0.010
ACE inhibitors or AT II
antagonist
14371/30530 (47.1) 7980/15652 (51.0) 6391/14878 (43.0) <0.001
Interventional therapy
Thrombolysis in STE-ACS 3508/17950 (19.5) 1346/9658 (13.9) 2162/8292 (23.1) <0.001
PCI primary 13744/30904 (44.5) 9086/15949 (57.0) 4658/14955 (31.1) <0.001
Any PCI 18167/26160 (69.4) 11426/14447 (79.1) 6741/11713 (57.6) <0.001
Data are presented as n/N (%) unless stated otherwise.
Table 2
Immediate therapies
in ACS patients
according to hospital
type.
Figure 1
Percutaneous
coronary intervention
(PCI) in patients with
STE-ACS according
to hospital type and
admission year
(N = 17931).
STE-ACS – ST-seg-
ment elevation acute
coronary syndrome
Hospitals type A –
large tertiary
teaching institutions
with round the clock
cardiac catheterisa-
tion facilities;
Hospitals type B –
small, regional
hospitals
318
Outcome of patients with acute coronary syndrome in hospitals of different sizes
1.16; p = 0.55) or MACE during hospitalisation
(OR 0.98, 95% CI 0.82–1.17; p = 0.84).
Hospital type was also not an independent
predictor of 1-year mortality or 1-year MACE in
patients with ACS. The adjusted odds ratio for
hospital type was 1.65 (95% CI 0.90–3.06;
p = 0.11) for 1-year mortality, and 1.1 (95% CI
0.85–1.32; p = 0.61) for 1-year MACE.
Total population A hospitals B hospitals p-value (A vs B)
In-hospital outcome
Number of patients: 31010 15987 15023
Cardiogenic shock 2060/30646 (6.7) 890/15814 (5.6) 1170/14832 (7.9) <0.001
Reinfarction 662/30583 (2.2) 260/15787 (1.6) 402/14796 (2.7) <0.001
Cerebrovascular event 299/30394 (1.0) 155/15713 (1.0) 144/14681 (1.0) 1.000
Death 2100/31010 (6.8) 987/15987 (6.2) 1113/15023 (7.4) <0.001
MACE (combined endpoint of
death, reinfarction and/or stroke)
2666/30 443 (8.8) 1241/15724 (7.9) 1425/14719 (9.7) <0.001
1-year outcome
Number of patients 3747 1515 2232
Reinfarction 123/3569 (3.4) 44/1460 (3.0) 79/2109 (3.7) 0.263
Rehospitalisation* 769/3585 (21.5) 306/1467 (20.9) 463/2118 (21.9) 0.482
Death 149/3747 (4.0) 43/1515 (2.8) 106/2232 (4.7) 0.004
MACE 1 (combined endpoint
of death, reinfarction and/or
rehospitalisation)
907/3716 (24.4) 346/1504 (23.0) 561/2212 (25.4) 0.102
Data are presented as n/N (%) unless stated otherwise.
* Rehospitalisation is defined as any rehospitalisation due to cardiovascular disease.
Table 3
Complications and
outcomes in ACS
patients according to
hospital type.
Odds ratio 95% confidence
interval
p
In-hospital mortality 0.94 0.76–1.16 0.552
In-hospital MACE
(combined endpoint of death, reinfarction and/or stroke)
0.98 0.82–1.17 0.837
1-year mortality 1.65 0.89–3.05 0.108
1-year MACE
(combined endpoint of death, reinfarction and/or rehospitalisation)
1.06 0.85–1.33 0.607
Table 4
Results of multivari-
ate regression
analyses.
Hospital type
adjusted for age, gen-
der, risk factors, type
of ACS and comor-
bidities as independ-
ent predictor of:
In-hospital mortality p duty vs
off-hours
1 year mortality p duty vs
off-hours
Admission during Duty-hours
(07–19h)
Off-hours (19–07h +
weekend)
Duty-hours
(7–19h)
Off-hours (19–7h +
weekend)
Hospitals type A 478/8364 (5.7) 475/7215 (6.6) 0.025 20/817 (2.4) 23/697 (3.3) 0.354
Hospitals type B 562/7977 (7.0) 539/6897 (7.8) 0.079 58/1190 (4.9) 44/1014 (4.3) 0.611
p (A vs B) 0.001 0.005 0.007 0.311
Table 5
Outcome in ACS
patients according to
admission time and
hospital type.
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Discussion
This analysis of the early and mid-term out-
comes of ACS patients according to hospital type
showed that patients admitted to smaller regional
hospitals differed from patients admitted to large
tertiary institutions in Switzerland; they were
older and sicker and consequently received less in-
tensive treatment. However, after accounting for
all clinical differences, hospital type bore no influ-
ence on in-hospital or 1-year mortality, the com-
posite endpoint of reinfarction, cerebrovascular
event and death in-hospital or the composite end-
point of reinfarction, any rehospitalisation for car-
diovascular reasons or death at 1-year follow-up.
The AMIS Plus registry allows a real-world
view of ACS management in Switzerland provid-
ing the opportunity to assess daily practice in a
large population of ACS patients.
Current political discussions on healthcare
delivery and quality of treatment take place in an
environment of increasing cost constraints on one
side and a growing impact of evidence-based med-
icine on the other side.Mostly, administrative data
of in-hospital mortality have been used as indica-
tors of the quality of care provided by a hospital
[12]. In the U.S.A., the public hospital marketing
department annually publishes a ranking list of
“best hospitals” using scores based on mortality
rate, patients’ safety and a subjective measurement
of reputation [13].Hospital rankings could change
dramatically depending on which data elements
and statistical methods are used to assess perfor-
mance [14]. Adequate comparisons of hospital
mortality rates require thorough adjustment for
differences among patients with baseline mortality
risk [3].
Outcomes in patients with ACS is dependent
on age [15], gender [8, 16], risk factors, type of
ACS [16, 17], comorbidities [16], delays [18–21]
and the medical [6] and interventional therapy re-
ceived [22]. The most relevant issues from a pa-
tient standpoint are advanced age and comorbidi-
ties [23]. Additionally, elderly patients across the
whole spectrum of ACS are less likely to receive
guideline-recommended therapies [7]. An un-
known number of very old ACS patients are also
refused interventional therapies, a topic that needs
to be addressed in the discussion on adherence to
guidelines and prognosis for these patients.
ACS encompasses the whole spectrum of
ischaemic status although there is a difference of
opinion in the literature [16, 17].Whether or not
ACS is a homogenous entity, prognosis seems to
depend on the type of ACS [16]. For this reason,
outcome was adjusted not only for risk factors and
comorbidities but also for the type of ACS.
As the patients initially admitted to type B
hospitals were older and sicker and consequently
received less intensive therapy, their mortality rate
in-hospital and at 1 year was higher than that of
patients initially admitted to type A hospitals
(7.4% vs 6.2%, 4.7% vs 2.8%, respectively). How-
ever, if one accounts for all the clinical differences
between these patients, there were no real signifi-
cant differences in the outcomes of patients
whether they were initially admitted to small or
large hospitals. An AMIS Plus study by Stolt et al.
implied differences between hospitals with and
without 24 hour PCI facilities in Switzerland;
however, no adjustments were made for comor-
bidities and follow-ups were not included [5].
PCI plays a central role in the therapeutic
management strategies for ACS patients. Starting
in the late 1990s, this procedure became the stand-
ard and is today the most frequently used therapy,
not only for STE-ACS patients but also for high-
risk NSTE-ACS or UA patients [24–25].The out-
come of patients who underwent PCI were similar
regardless of whether patients presented at a PCI
centre or were transferred for intervention [26].
The same results are shown in a recently pub-
lished study on STE-ACS patients fromDenmark
[27] that also found no difference in outcome ac-
cording to admission during working or off-duty
hours. In an earlier study, we showed that the out-
come of STE-ACS patients admitted out of duty
hours was the same as for those patients admitted
during regular duty hours [28]. In this study, simi-
lar percentages of ACS patients were admitted
during off-hours to type A and type B hospitals.
A study from Belgium using administrative data-
bases found there was no better outcome for pa-
tients initially admitted to hospitals with catheter-
isation facilities compared with those admitted to
hospitals without, although the former delivered
more expensive care [29]. In contrary to these and
the current results, a French study conducted in
2000 at nearly 900 hospitals, which included 1914
STEMI patients, showed that admission to PCI
hospitals was associated with greater use of PCI
and improved 1-year survival [1]. This could be
because only 1.2% of patients from non-PCI hos-
pitals underwent primary PCI compared to 31.1%
in AMIS Plus patients. In this study, patients ini-
tially admitted to type B hospitals and not trans-
ferred to type A hospitals for intervention were
older, sicker, arrived later and in a worse condition
with less frequent STE-ACS compared with trans-
ferred patients. This could suggest that in the
smaller hospitals the physicians in charge do an
excellent job in triaging to the greatest benefit of
the patients. Furthermore, it could indirectly
mean that the guidelines for treatment of ACS pa-
tients were well implemented in all Swiss hospitals
participating in AMIS Plus regardless of hospital
category and that these hospitals have been func-
tioning as an efficient network for the past 12
years.
Currently, access to medical and interven-
tional therapies in Switzerland is guaranteed for
everyone regardless of age, insurance, income or
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residency. The type of hospital at which the pa-
tient initially presented does not appear to be im-
portant providing the guideline recommendations
for treatment are followed. Optimal effect can
only be achieved within an efficient organisational
healthcare structure. These observations with re-
gard to the care of ACS contrast with statements
in the lay press regarding patients with tumours. If
these patients can be documented by registry or
other hard data, a detailed analysis with regard to
the differences between care for heart and care for
cancer patients can be conducted.
In the USA, a number of top hospitals fell
short of regularly applying evidence-based care
for their heart patients, but many lesser known
hospitals routinely provided cardiovascular care
consistent with nationally established guidelines
[30]. A published analysis of the most recent data
at a national level placed the readmission rate as a
marker for quality to help hospitals identify and
address issues for improvement [31].The all-cause
rehospitalisation rate of the patients who under-
went PCI within 30 days of discharge was around
15%, with wide variations between the examined
hospitals [32]. In our analysis, the rate of readmis-
sion for any cardiovascular reason during the first
year after initial hospitalisation for all ACS pa-
tients was high but comparable irrelevant of
whether patients presented at type A or type B
hospitals (20.9% vs 21.9%; p = 0.48).
While we found that crude in-hospital and
1-year mortality was higher in ACS patients ini-
tially admitted into type B hospitals, after multi-
variate adjustment that accounted for age, gender,
risk factors, ACS type and comorbidities, both
short- and mid-term outcomes for patients ini-
tially admitted to types A or B hospitals in Swit-
zerland were similar.
Limitations
Although the data was collected prospectively,
these are registry data from hospitals participating
voluntarily, which does require highly motivated
staff in charge of the patients with heart disease.
Therefore, not all patients treated for ACS in
Switzerland were included and there was no con-
trol as to whether all patients treated in the partic-
ipating institutions were included. This may have
produced an undetected selection bias. However,
the great number of patients and hospitals in-
cluded in this study appears to be representative of
the Swiss population. In December 2004, an inde-
pendent physician reviewed hospital case records
on a random sample of 20 patients for internal val-
idation which demonstrated good agreement with
the data obtained from questionnaires (κ scores
>0.8 for baseline data and therapeutic interven-
tions). The error rate was 0% for therapeutic in-
terventions, 0–0.9% for baseline characteristics
and 1.2% for time variables (e.g., time of symptom
onset, time of PCI).
In this study, we focused on the impact of the
type of admission hospital on the overall outcome
of ACS patients in Switzerland and did not assess
adherence to guideline-recommended medical or
interventional therapies. Furthermore, this study
covers a 12-year span, reflecting all the changes in
diagnostics and treatments over these years. The
AMIS Plus questionnaire has been revised several
times in order to keep pace with the latest devel-
opments in ACS care, necessitating additional var-
iables.
This study showed that ACS patients admitted
to smaller regional Swiss hospitals were older, had
more severe comorbidities,more NSTE-ACS and
received less intensive treatment compared with
the patients initially admitted to large tertiary in-
stitutions.However, hospital type was not an inde-
pendent predictor of early and mid-term out-
comes in patients with ACS. Furthermore, the
AMIS Plus data suggested that Swiss hospitals
have been functioning as an efficient network for
the past 12 years.
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AMIS Plus Participants 1997–2009
The following hospitals participated in the AMIS registry
from 1997–2009 on which this report is based (in alphabeti-
cal order): Affoltern am Albis, Bezirkspital (F. Hess), Altdorf,
Kantonsspital (R. Simon), Altstätten, Kantonales Spital (P.J.
Hangartner), Aarau, Kantonsspital (P. Lessing), Baden,
Kantonsspital (U. Hufschmid), Basel, Kantonsspital (P.
Hunziker), Basel, St. Claraspital (C. Grädel), Bern, Beau-Site
Klinik (A. Schönfelder), Bern, Inselspital (S. Windecker), Biel,
Spitalzentrum (H. Schläpfer), Brig-Glis, Oberwalliser
Kreisspital (D. Evéquoz), Bülach, Spital (A. Vögele), Burgdorf,
Regionalspital Emmental (D. Ryser), Chur, Rätisches
Kantons- und Regionalspital (P Müller), Chur, Kreuzspital
(R. Jecker), Davos, Spital (G. Niedermaier), Dornach, Spital
(A. Droll /T. Hongler), Einsiedeln, Regionalspital (S. Stäuble),
Flawil, Kantonales Spital (J. Haarer), Frauenfeld, Kantonsspi-
tal (H.P. Schmid), Fribourg, Hôpital cantonal (B. Quartenoud),
Frutigen, Spital (K. Bietenhard), Genève, Hôpitaux universi-
taires (HUG) (J.M. Gaspoz/P.F. Keller), Glarus, Kantonsspital
(W.Wojtyna), Grenchen, Spital (B. Oertli / R. Schönenberger),
Grosshöchstetten, Bezirksspital (C. Simonin), Heiden,
Kantonales Spital (R. Waldburger), Herisau, Kantonales
Spital (M. Schmidli), Interlaken, Spital (E.M.Weiss),
Jegenstorf, Spital (H. Marty), La Chaux-de-Fonds, Hôpital
(H. Zender), Lachen, Regionalsspital (C. Steffen), Langnau im
Emmental, Regionalspital (A. Hugi), Laufenburg, Gesund-
heitszentrum Fricktal (E. Koltai), Lugano, CardiocentroTicino
(G. Pedrazzini), Luzern, Kantonsspital (P. Erne), Männedorf,
Kreisspital (T. Luterbacher), Martigny, Hôpital régional
(B. Jordan), Mendrisio, Ospedale regionale (A. Pagnamenta),
Meyrin, Hôpital de laTour (P. Urban), Monthey, Hôpital du
Chablais (P. Feraud), Montreux, Hôpital de Zone (E. Beretta),
Moutier, Hôpital du Jura bernois (C. Stettler), Münsingen,
Regionales Spital Zentrum (F. Repond), Münsterlingen,
Kantonsspital (F. Widmer), Muri, Kreisspital für das Freiamt
(H. Lusser), Nyon, Group. Hosp. Ouest lémanique (R.
Polikar), Olten, Kantonsspital (S. Bassetti), Rheinfelden,
Gesundheitszentrum Fricktal (H.U. Iselin), Rorschach,
Kantonales Spital (M. Giger), Samedan, Spital Oberengadin
(P. Egger), Sarnen, Kantonsspital Obwalden (T. Kaeslin),
Schaffhausen, Kantonsspital (R. Frey), Schlieren, Spital
Limmattal (T. Herren), Schwyz, Spital (P. Eichhorn), Scuol,
Ospidal d’Engiadina Bassa (C. Neumeier), Solothurn,
Bürgerspital Solothurn (A. Grêt/ R. Schöneneberger),
St. Gallen, Kantonsspital (H. Rickli), Sursee, Spital (S.Yoon),
Tiefenau,Tiefenauspital (P. Loretan),Thun, Spital (U Stoller),
Thusis, Krankenhaus (U.P. Veragut), Uster, Spital (E. Bächli),
Uznach, Kantonales Spital (A. Weber), Wädenswil, Schwer-
punktspital Zimmerberg-Horgen (B. Federspiel / M.
Weisskopf), Walenstadt, Kantonales Spital (D. Schmidt /
J. Hellermann), Wetzikon, GZO Spital (M. Graber), Winter-
thur, Kantonsspital (A. Haller), Wolhlusen, Kantonales Spital
(M. Peter), Zoﬁngen, Spital (S. Gasser), Zollikerberg, Spital
(P. Siegrist / R. Fatio), Zug, Kantonsspital (M. Vogt /
D. Ramsay), Zürich, Klinik im Park (O. Bertel), Zürich,
Universitätsspital Zürich (M. Maggiorini), Zürich, Stadtspital
Triemli (F. Eberli), Zürich, Stadtspital Waid (S. Christen).
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